Glycosylation is a common post-translational modification of proteins. It is known, that glycans 46 are directly involved in the pathophysiology of every major disease. Defining genetic factors 47 altering glycosylation may provide a basis for novel approaches to diagnostic and pharmaceutical 48 applications. Here, we report a genome-wide association study of the human blood plasma N-49 glycome composition in up to 3811 people. We discovered and replicated twelve loci. This 50 allowed us to demonstrate a clear overlap in genetic control between total plasma and IgG 51 glycosylation. Majority of loci contained genes that encode enzymes directly involved in 52 glycosylation (FUT3/FUT6, FUT8, B3GAT1, ST6GAL1, B4GALT1, ST3GAL4, MGAT3, and 53 MGAT5). We, however, also found loci that are likely to reflect other, more complex, aspects of 54 plasma glycosylation process. Functional genomic annotation suggested the role of DERL3, which 55 potentially highlights the role of glycoprotein degradation pathway, and such transcription factor 56 as IKZF1. 57 58 59
Introduction Plasma glycome paper
Previous genome-wide association studies (GWAS) of total plasma protein N-glycome 74 measured with high performance liquid chromatography (HPLC) discovered six loci associated 75 with protein glycosylation [26, 27] . Four of these contained genes that have well characterized 76 roles in glycosylation: the fucosyltransferases FUT6 and FUT8, glucuronyltransferase B3GAT1, 77 and glucosaminyltransferase MGAT5. Other two loci-one near SLC9A9 on chromosomes 3 and 78 one near HNF1a on chromosome 12-did not contain any genes known to be involved in 79 glycosylation processes. A functional in vitro follow-up study in HepG2 cells [27] on the HNF1a 80 locus on chromosome 12, showed that its gene product acts as a co-regulator of expression of most 81 fucosyltransferase genes (FUT3, FUT5, FUT6, FUT8, FUT10, FUT11 ). In addition, it co-regulates 82 expression of genes encoding key enzymes required for the synthesis of GDP-fucose, the substrate 83 of these fucosyltransferases. It was concluded that HNF1a is one of the master regulators of 84 protein glycosylation, influencing both core and antennary fucosylation [26] . The locus on 85 chromosome 3 contained SLC9A9, a gene that encodes a proton pump which affects pH in the 86 endosomal compartment, reminiscent of recent findings that changes in Golgi pH can impair 87 protein sialylation, suggesting a possible mechanism for the observed association with N-88 glycosylation traits. 89
Since 2011, when the latest GWAS of plasma N-glycome was published, new technologies 90 for glycome profiling were developed [28] . Ultra-performance liquid chromatography (UPLC) 91 became a widely used technology for accurate analysis of plasma N-glycosylation due to its 92 superior sensitivity, resolution, speed, and its capability to provide branch-specific information of 93 glycan structures [29] . Moreover, new imputation panels (such as 1000 Genomes [30] and HRC 94
[31]) became available, increasing the resolution and power of genetic mapping. 95
In this work, we aimed to advance our understanding of the genetic control of the human 96 plasma N-glycome, and to establish a public resource that will facilitate future studies linking 97 glycosylation and complex human diseases. For that, we performed and reported results of GWAS 98 on 113 plasma glycome traits measured by UPLC and genotypes imputed to the 1000 Genomes 99 reference panel in 2,763 participants of TwinsUK. Further we replicated our findings in 1,048 100 samples from three independent and genetically diverse cohorts -PainOR, SOCCS and QMDiab. Replication of previously reported loci 104 We started with replication of six loci that were reported previously. Huffman and colleagues [27] 105 analyzed four independent cohorts with total sample size of 3,533, using plasma N-glycome 106 measured with HPLC. Because of technological differences, there is no one-to-one correspondence 107 between HPLC and UPLC traits, and exact replication is not possible. Therefore, we analyzed 108 association of the SNPs reported by [27] with all 113 UPLC traits measured in this study, and 109 considered a locus replicated if we observed P-value < 0.05/(6×30) = 2.78 × 10 -4 (where 30 is a 110 number of principal components, explaining 99% of the variation of the 113 studied traits) in the 111 TwinsUK cohort (N=2,763). Using this procedure, we replicated 5 of the 6 previously reported 112
SNPs (Table 1) . For more details, see Supplementary Table 1 . 113
These results not only confirm previous and establish five plasma glycome loci as 114
replicated, but also demonstrate that our study is well powered (among replicated loci, all P-value 115 were less than 4 × 10 -7 ). 
Discovery and replication of new loci 124
The discovery cohort comprised 2,763 participants of the TwinsUK study with genotypes available 125 for 8,557,543 SNPs. The genomic control inflation factor varied from 0.99 to 1.02, suggesting that 126 influences of residual population stratification on the test statistics were small (see Supplementary  127   Table 2 ; QQ-plots in Supplementary Figure 1 ). In total, 906 SNPs located in 14 loci were 128 6 Plasma glycome paper significantly associated (P-value < 5 x 10 -8 / 30 = 1.66 x 10 -9 , where 30 is a number of principal 129 components, explaining 99% of the variation of the 113 studied traits) with at least one of 113 130 glycan traits (in total 5,052 SNP-trait associations, see Figure 1 , Table 1 ). Out of 113 traits, 68 131 were significantly associated with at least one of the 14 loci. For more details, see Supplementary  132   Table 3 . 133 134 143 Among fourteen loci, four were previously reported as associated with the plasma N- Ten further loci that have not been reported before were found here. In order to replicate 152 our findings, we have performed association analysis of these ten SNPs in three independent 153 cohorts-PainOR, SOCCS and QMDiab (total N =1,048)-and then meta-analyzed the results. 154
Seven of ten novel loci were replicated at threshold P-value < 0.05/10 = 0.005 (see Table 2 ). The 155 direction of association was concordant between discovery and replication for all ten loci. The 156 effects of loci between the replication cohorts were homogeneous (P-value of Cochran's Q-test 157 varied from 0.07 to 0.96, see Supplementary Table 3 ). 158
Given seven replicated novel loci found in this study and five loci found previously and 159 replicated in this study we now have 12 replicated loci in total. 
Analysis of possible effects of genetic variants with VEP 170
We have used variant effect predictor [32] in order to find functional variants that potentially 171 disturb amino acid sequence and may explain association in some loci. For that, within each locus, 172
we identified a set of SNPs that are likely to contain the functional variant by selecting SNPs that 173 had association p-value deviating from the minimal p-value by less than one order of magnitude. 
Gene-set and tissue/cell enrichment analysis 185
For prioritizing genes in associated regions (based on their predicted function) and gene set and 186 tissue/cell type enrichment analyses we used DEPICT software [35] . When running DEPICT 187 analyses on the 14 genome-wide significant loci (from Table 1 ) we identified tissue/cell type 188 enrichment (with FDR<0.05) for six tissue/cell types: plasma cells, plasma, parotid gland, salivary 189 glands, antibody producing cells and B-lymphocytes (see Supplementary Table 5c ). We did not 190 identify any significant enrichment for gene-sets (all FDR > 0.2, Supplementary Table 5b ). Based 191 on predicted gene function and reconstituted gene sets, DEPICT suggestively prioritized three 192 genes -FUT3, DERL3 and FUT8 for three loci (on chromosome 19 at 58 Mb, on chromosome 22 193 at 24 Mb and on chromosome 14 at 65/66 Mb) with FDR < 0.20 (see Supplementary Table 5a ). 194
We have also analyzed 93 loci with P-value < 1 x 10 -5 /30 ( Supplementary Table 6 ), however, all 195 results had FDR > 0.2. 196 9 Plasma glycome paper Overlap with complex traits 197 We next investigated the potential pleiotropic effects of our loci on other complex human traits 198 and diseases, using PhenoScanner v1.1 database [36] . For twelve replicated SNPs (Table 1 and 199 Table 2), we looked up traits that were genome-wide significantly (P-value< 5 x 10 -8 ) associated 200 with the same SNP or a SNP in strong (r 2 < 0.7) linkage disequilibrium. The results are 201 summarized in Supplementary Table 7 
Pleiotropy with eQTLs 213
We next attempted to identify genes whose expression levels could potentially mediate the 214 association between SNPs and plasma N-glycome. For this we performed a summary-data based 215
Mendelian randomization (SMR) analysis followed by heterogeneity in dependent instruments 216 (HEIDI) analysis [44] using a collection of eQTL data from a range of tissues, including blood 217
[45], 44 tissues as provided in the GTEx database version 6p [46] and six blood cell lines collected 218 in the CEDAR study (see Supplementary Note 3 and [47]) -five immune cell populations (CD4+, 219 CD8+, CD19+, CD14+, CD15+) and platelets. In short, SMR test aims at testing the association 220 between gene expression (in a particular tissue) and a trait using the top associated SNP as a 221 genetic instrument. Significant SMR test may indicate that the same functional variant determines 222 both expression and the trait of interest (causality or pleiotropy), but may also indicate the 223 possibility that functional variants underlying gene expression are in linkage disequilibrium with 224 those controlling the traits. Inferences whether functional variant may be shared between plasma 225 Plasma glycome paper glycan trait and expression were made based on HEIDI test: P HEIDI > 0.05 (likely shared), 0.05 226 >P HEIDI > 0.001 (possibly shared), P HEIDI < 0.001 (sharing is unlikely). 227
We applied SMR/HEIDI analyses for replicated loci that demonstrated genome-significant 228 association in our discovery data (11 loci in total). In total, we included in the analysis expression 229 levels of 20,448 transcripts (probes). For fifteen probes located in seven loci associated with 230 plasma glycosylation we observed significant (P SMR < 0.05/20,448=2.445 x 10 -6 ) association to the 231 top SNPs associated with plasma N-glycome (see Supplementary Table 8 Summary of in-silico follow-up 253 We compared the genes suggested by our in silico functional investigation with candidate genes 254 suggested previously for five known loci (see Table 3 ). For three out of five loci (B3GAT1, FUT8, 255 FUT6/FUT3) we selected the same genes as suggested by the authors of previous study [27] . All 256 three genes are known to be involved into the glycan synthesis pathways. The FUT8 locus was 257 associated mostly with core-fucosylated biantennary glycans, that are known to be linked to the 258 immunoglobulins [9]. As FUT8 gene codes fucosyltransferase 8, an enzyme responsible for the 259 Plasma glycome paper addition of core fucose to glycans, this gene is most biologically plausible in this locus. FUT3 and 260 FUT6 encode fucosyltransferases 3 and 6 that catalyze the transfer of fucose from GDP-beta-261 fucose to alpha-2,3 sialylated substrates. The FUT3/FUT6 locus was associated with antennary 262 fucosylation of tri-and tetra-antennary sialylated glycans, and therefore we consider these genes as 263 Four of the seven novel loci contain genes that are known to be involved in glycan 277 synthesis pathways -ST6GAL1, ST3GAL4, B4GALT1 and MGAT3 (see Table 3 ). Moreover, 278 summary level Mendelian randomization (SMR) and HEIDI analyses have shown that expression 279 of ST6GAL1 and MGAT3 genes may mediate the association between corresponding loci and 280 plasma N-glycome. ST6GAL1 and ST3GAL4 genes encode sialyltransferases, enzymes which 281 catalyze the addition of sialic acid to various glycoproteins. The locus containing ST6GAL1 was 282 associated with ratio of sialylated and non-sialylated galactosylated biantennary glycans. The locus 283
containing ST3GAL4 was associated with galactosylated sialylated tri-and tetra-antennary glycans. 284
The locus containing MGAT3 was associated with proportion of bisected biantennary glycans. This 285 latter gene encodes the enzyme N-acetylglucosaminyltransferase, which is responsible for the 286 addition of bisecting GlcNAc. The B4GALT1 gene encodes galactosyltransferase, which adds 287 galactose during the biosynthesis of different glycoconjugates. This gene was associated with 288 galactosylation of biantennary glycans. Thus, we observe consistency between known enzymatic 289 13 Plasma glycome paper activities of the products of selected candidate genes and the spectrum of glycans that are 290 associated with corresponding loci. 291
The other three novel loci do not contain genes that are known to be directly involved in 292 glycan synthesis. Variant rs9624334 (chromosome 22 at 24 Mb) is located in the intron of 293 SMARCB1 gene that is known to be important in antiviral activity, inhibition of tumor formation, 294 neurodevelopment, cell proliferation and differentiation [49] . However, gene prioritization 295 analysis (DEPICT) showed, that the possible candidate gene is DERL3, which encodes a 296 functional component of endoplasmic reticulum (ER)-associated degradation for misfolded 297 luminal glycoproteins [50] (see Table 3 ). Additionally, VEP analysis demonstrated that the leading 298 rs9624334 variant in this locus is in strong LD (R 2 =0.98 in 1000 Genome EUR samples) with 299 rs3177243, which is a DERL3 coding variant predicted to be deleterious by SIFT and PolyPhen. 300
However, the SMR/HEIDI analysis suggested that the association with N-glycome could be (also) 301 mediated by expression of CHCHD10 gene, which encodes a mitochondrial protein that is 302 enriched at cristae junctions in the intermembrane space. The CHCHD10 gene has the highest 303 expression in heart and liver and the lowest expression in spleen [51] . While the role of 304 mitochondrial proteins in glycosylation processes remains speculative, we propose CHCHD10 as a 305 candidate based on our eQTL pleiotropy analysis. Thus, we consider two genes -DERL3 and 306 CHCHD10 -as possible candidate genes at this locus. Interestingly, this and the MGAT3 loci were 307 associated with similar glycan traits (core-fucosylation of bisected glycans). This indicates that 308 core fucosylation of bisected glycans is under joint control of MGAT3 and DERL3/CHCHD10. 309
The locus on chromosome 14 at 105 Mb contains the IGH gene that encodes 310 immunoglobulin heavy chains. This locus is associated with sialylation of core-fucosylated 311 biantennary monogalactosylated structures that are biochemically close to those affected by 312 ST6GAL1 gene. As IgG is the most prevalent glycosylated plasma protein [9], one would consider 313 IGH as a good candidate, as indeed was suggested by Shen and colleagues [48] . However, our 314 functional annotation results (SMR/HEIDI and VEP) suggest that association of this locus with 315 plasma N-glycome may be mediated by regulation of expression of TMEM121 gene. This gene 316 encodes transmembrane protein 121 that is highly expressed in heart as well as being detected in 317 pancreas, liver and skeletal muscle. Moreover, for the lead SNP rs35590487 we found a variant 318 rs10569304 that is in strong linkage disequilibrium (R 2 =0.95 In 1000 Genome EUR samples) with 319 Plasma glycome paper it, and which leads to inframe deletion in protein coding region of the TMEM121 gene. Therefore, 320
we consider two genes -IGH and TMEM121-as candidate genes for this locus. 321
For the locus on chromosome 7 at 50 Mb we were not able to select a candidate gene based 322 on results of our in-silico functional annotation. This locus was previously reported to be 323 associated with glycan levels of IgG [13] , and authors suggested that IKZF1 may be considered as 324 a candidate gene in the region. The IKZF1 gene codes the DNA-binding protein Ikaros that acts as 325 a transcriptional regulator and is associated with chromatin remodeling. It is considered an 326 important regulator of lymphocyte differentiation. Taking into account that IgG (the most 327 abundant glycoprotein in the blood plasma [9]) are secreted by B cells [52], IKZF1 seems to be a 328 plausible candidate gene. 329
To identify possible clusters in the gene network of plasma N-glycosylation we draw a 330 graph in which eleven genome-wide significant loci and genome-wide significantly (P-value < 331 1.66 × 10 -9 ) associated glycan traits were presented as nodes, and edges represent observed 332 significant associations (see Figure 2 ). We labeled each glycan trait as "immunoglobulin-linked" 333 (Ig-linked), "non-immunoglobulin-linked" (non-Ig-linked) or mixed (could be linked to either) 334 depending on the contribution of Ig and non-Ig linked glycans to the trait value (see 335 Supplementary Table 9 ), which was inferred based on information about protein-specific 336 glycosylation reported previously in [9] . For more details about the procedure of Ig/non-Ig/mixed 337 assignment see Supplementary Note 4. 338
The resulting network ( Figure 2) shows that candidate genes and glycan traits cluster into 339 two major subnetworks or hubs. The first subnetwork contained the six loci: FUT8, 340 DERL3/CHCHD10, IKZF1, TMEM121, ST6GAL1, and MGAT3, with FUT8 as a hub. These loci, 341 as well as the locus containing B4GATL1, were associated with core-fucosylated biantennary 342 glycans. It is known that the majority of plasma core-fucosylated biantennary glycans are linked to 343 immunoglobulins [9]. Moreover, in previous studies these seven genes were found to be associated 344 with N-glycosylation of IgG [13, 48] . At the same time these genes were associated with non-345 immunoglobulins linked glycans. We can consider this cluster (seven genes out of eleven) as 346 related to both IgG and non-IgG glycosylation. Taking into account that IgG is the most prevalent 347 glycosylated plasma protein, it is not surprising that more than a half of replicated loci are actually 348 associated with immunoglobulins glycosylation. However, previous GWAS on HPLC plasma N-349 glycome reported only one locus -FUT8 -overlapping with IgG loci. Plasma glycome paper
The second subnetwork in Figure 2 contained four loci (ST3GAL4, HNF1a, FUT3/FUT6, 351 and B3GAT1, with FUT3/FUT6 as a hub) associated with tri-and tetra-antennary glycans. It is 352 known that these types of glycans are linked to plasma proteins other than IgG [9]. Thus we relate 353 this cluster to non-IgG plasma protein N-glycosylation. Among these four loci we report ST3GAL4 354 as the novel locus controlling the N-glycosylation of non-IgG plasma proteins. We attribute it to 355 non-immunoglobulins plasma protein N-glycosylation owing to its association with tetra-356 antennary glycans. 357
358

Figure 2. A network view of associations between loci and glycan traits. Square nodes 360
represent genetic loci labeled with the names of candidate gene(s), circle nodes represent glycan 361 traits. Green highlights candidate genes, located in genomic regions that were previously found to 362 be associated with IgG N-glycome. Yellow highlights candidate genes, located in genomic regions 363 associated with plasma N-glycome. Pink color highlights glycan traits mostly containing glycans 364
that are linked to immunoglobulins. Blue color highlights traits that are mostly formed by glycans 365 linked to other (not immunoglobulin) proteins. Blue/pink color highlights glycan traits, formed by 366 a mixture of glycans that are linked to immunoglobulin and non-immunoglobulin proteins. Arrows 367
represent genetic association (P-value < 1.66 x 10 -9 ) between gene and specific glycan. 368 Plasma glycome paper Discussion 369 We conducted the first genome-wide association study of total plasma N-glycome measured by 370 UPLC technology. Our efforts brought the number of loci significantly associated with total 371 plasma N-glycome from 6 [26,27] to 16, of which 12 were replicated in our work. This allowed us 372 to next use a range of in-silico functional genomics analyses to identify candidate genes in the 373 established loci and to obtain insight into biological mechanisms of plasma glycome regulation. instead of HapMap in the previous studies) that more than tripled the number of polymorphisms 380 analyzed genome-wide (from 2.4M SNPs to 8M). That may have contributed to the higher power 381 of our study as well. In addition to detecting novel loci, we were able to replicate five (HNF1a, 382 FUT6, FUT8, B3GAT1 and MGAT5) of six loci that were reported previously to be associated with 383 human plasma N-glycome measured using the HPLC technology [26, 27] . 384
Among six plasma glycome loci that were identified as genome-wide significant previously 385 overlap between plasma and IgG glycome loci to two. In our study, among 12 replicated loci, 389 majority (eight) overlap with loci that were reported to be associated with IgG glycome 390 composition [13,48] (see Figure 2 ). We therefore clearly establish a strong overlap between IgG 391 and plasma glycome loci. 392
In a way, this overlap is to be expected. It is known that majority of serum (and therefore 393 plasma) glycoproteins are either immunoglobulins produced by B-lymphocytes or glycoproteins 394 secreted by the liver [53] . We thus expected overlap between IgG and total plasma glycome loci, 395 and we expected that loci associated with the plasma N-glycome would be enriched by genes with 396 tissue specific expression in liver and B-cells. Indeed, we find that plasma N-glycome loci are 397 enriched for genes expressed in plasma cells, antibody producing cells and B-lymphocytes, and we 398 also find overlap between plasma N-glycome loci and CD19+ eQTLs. However, we neither find 399 Plasma glycome paper enrichment of genes that are expressed in liver ( Supplementary table 5c ), nor overlap between 400 plasma N-glycome loci and liver eQTLs. In the future, it will be important to achieve better 401 resolution and separation of loci that are related to glycosylation of non-immunoglobulin 402 glycoproteins. This could be achieved either technologically (e.g. performing analyses of IgG-free 403 fractions of proteins), or this could be attempted via statistical modelling. 404
The genetic variation in the FUT3/FUT6 locus is a major (in terms of proportion of 405 variance explained and number of glycans affected) genetic factor for non-immunoglobulins 406
glycosylation. According to current knowledge, these enzymes catalyze fucosylation of antennary 407
GlcNAc32, resulting in glycan structures that are not found on IgG [9, 54] . This is consistent with 408 the spectrum of glycan traits associated with FUT3/FUT6 locus in our work (Figure 2 ). However, 409 this locus was recently found to be associated with IgG glycosylation [48] . The authors could not 410 explain this finding because at that time IgG glycans were not known to contain antennary fucose. An interesting pattern starts emerging out of study of genetic control of plasma 419 glycosylation. We now see a clear overlap in genetic control between plasma and IgG 420 glycosylation, which calls for future studies that would help distinguish between global, cell-, 421 tissue-, and protein-specific pathways of protein glycosylation. Many (eight out of twelve) 422 replicated loci contained genes that encode enzymes directly involved in glycosylation 423 FUT6, FUT8, B3GAT1, ST6GAL1, B4GALT1, ST3GAL4, MGAT3, and MGAT5) . We, 424 however, start now seeing loci and genes, which are likely to reflect other, more complex, aspects 425 of plasma glycosylation process. These genes include DERL3, which potentially highlights the role 426 of glycoprotein degradation pathway, and such transcription factors as HNF1a and IKZF1. Such 427 regulatory genes, in our view, are plausible candidates that will help linking glycans and complex 428 human disease. This view is supported by an example of mutations in HNF1a, that lead to maturity 429 onset diabetes of the young (MODY), and to strong distortion of plasma glycosylation profile [24] . QMDiab. Sample demographics can be found in Supplementary Table 10 . 457
TwinsUK 458
The TwinsUK cohort [56] (also referred to as the UK Adult Twin Register) is an a nationwide 459 registry of volunteer twins in the United Kingdom, with about 13,000 registered twins (83% 460 female, equal number of monozygotic and dizygotic twins, predominantly middle-aged and older). (HMC) in Doha, Qatar. Inclusion criteria were a primary form of type 2 diabetes (for cases) or an 473 absence of type 2 diabetes (for controls). Sample collection was conducted in the afternoon, after 474 the general operating hours of the morning clinic. Patient and control samples were collected in a 475 random order as they became available and at the same location using identical protocols, 476 instruments and study personnel. Samples from cases and controls were processed in the 477 laboratory in parallel and in a blinded manner. Data from five participants were excluded from the 478 analysis because of incomplete records, leaving 176 patients and 193 controls. Of the 193 control 479 participants initially enrolled, 12 had HbA1c levels above 6.5% (48 mmol/mol) and were 480 subsequently classified as cases, resulting in 188 cases and 181 controls. 481
SOCCS 482
SOCCS study [59, 60] and Local Research Ethics committee. Sample collection is described in [59, 60] . For full details of the genotyping and imputation see Supplementary Table 11 . 514 25 Plasma glycome paper Genome-wide association analysis 604 Discovery GWAS was performed using TwinsUK cohort (N = 2,763) for 113 GP traits. GEMMA 605
[67] was used to estimate the kinship matrix and to run linear mixed model regression on SNP 606 dosages assuming additive genetic effects. Obtained summary statistics were corrected for 607 genomic control inflation factor λ GC to account for any residual population stratification. An 608 association was considered statistically significant at the genome-wide level if the P-value for an 609 individual SNP was less than 5 x 10 -8 / (29+1) = 1.66 x 10 -9 , where 29 is an effective number of 610 tests (traits) that was estimated as the number of principal components that jointly explained 99% 611 of the total plasma glycome variance in the TwinsUK sample. 612
Locus definition 613
In short, we considered SNPs located in the same locus if they were located within 500 Kb from 614 the leading SNP (the SNP with lowest P-value). Only the SNPs and the traits with lowest P-values 615 are reported (leading SNP-trait pairs). The detailed procedure of locus definition is described in 616 Supplementary Note 1. 617
Replication 618
We have used TwinsUK cohort for the replication of six previously described loci [27] affecting 619 plasma N-glycome. From each of six loci we have chosen leading SNP with the strongest 620 association as reported by authors [27] . Since there is no direct trait-to-trait correspondence 621 between glycan traits measured by HPLC and UPLC technologies we tested the association of the 622 leading SNPs with all 113 PGPs in TwinsUK cohort. We considered locus as replicated if its 623 leading SNP showed association with at least one of 113 PGPs with replication threshold of P-624 value<0.05/(6*30) = 2.78 x 10 -4 , where six is number of loci and 30 is a number of principal 625 components that jointly explained 99% of the total plasma N-glycome variance. 626
For the replication of novel associations, we used data from 3 cohorts: PainOR (N = 294), 627
QMDiab (N = 327) and SOCCS (N = 472) with total replication sample size of N = 1,048 samples 628 that have plasma UPLC N-glycome and genotype data (for details of genotyping, imputation and 629 association analysis, see Supplementary Table 11 ). We used only the leading SNPs and traits for 630 the replication that were identified in the discovery step. For these SNPs we conducted a fixed-631 effect meta-analysis using METAL software [68] combining association results from three 632 Plasma glycome paper cohorts. The replication threshold was set as P-value<0.05/10=0.005, where 10 is the number of 633 replicated loci. Moreover, we checked whether the sign of estimated effect was concordant 634 between discovery and replication studies. 635
Functional annotation in-silico
636
Variant effect prediction (VEP) 637
For annotation with the variant effect predictor (VEP, [32]), for each of the 12 replicated loci we 638 have selected the set of SNPs that had strong associations, defined as those located within +/-639 250kbp window from the strongest association, and having P-value<T, where 640 log10(T)=log10(P min )+1, where P min is the P-value of the strongest association in the locus. 641
Gene-set and tissue/cell enrichment analysis 642
To prioritize genes in associated regions, gene set enrichment and tissue/cell type enrichment 643 analyses were carried out using DEPICT software v. 1 rel. 194 [35] . For the analysis we have 644 chosen independent variants (see "Locus definition") with P-value <5 x 10 -8 /30 (14 SNPs) and P-645 value <1x10 -5 /30 (93 SNPs). We used 1000G data set for calculation of LD [69]s. 646
Pleiotropy with complex traits 647
We have investigated the overlap between associations obtained here and elsewhere, using 648 PhenoScanner v1.1 database [36] . For twelve replicated SNPs (Table 1, Table 2 ) we looked up 649 traits that have demonstrated genome-wide significant (p < 5 × 10−8) association at the same or at 650 strongly (r2 < 0.7) linked SNPs. 651
Pleiotropy with eQTLs 652
To identify genes whose expression levels could potentially mediate the association between SNPs 653 and plasma glycan traits we performed a summary-data based Mendelian randomization (SMR) 654 analysis followed by heterogeneity in dependent instruments (HEIDI) method [44] . In short, SMR 655 test aims at testing the association between gene expression (in a particular tissue) and a trait using 656 the top associated expression quantitative trait loci (eQTL) as a genetic instrument. Significant 657 SMR test indicates evidence of causality or pleiotropy but also the possibility that SNPs 658 controlling gene expression are in linkage disequilibrium with those associated with the traits. 659
These two situations can be disentangled using the HEIDI (HEterogeneity In Dependent 660 Instrument) test. 661
